Skip to main content
Aarti Pharmalabs Limited logo

Aarti Pharmalabs Limited — Investor Relations & Filings

Ticker · AARTIPHARM ISIN · INE0LRU01027 LEI · 335800TTAKRBNDK5P363 BSE.NS Manufacturing
Open in API
Filings indexed 246 across all filing types
Latest filing 2024-02-01 Regulatory Filings
Country IN India
Listing BSE.NS AARTIPHARM

About Aarti Pharmalabs Limited

https://www.aartipharmalabs.com/

Aarti Pharmalabs Limited is a manufacturer of Active Pharmaceutical Ingredients (APIs), pharmaceutical intermediates, and xanthine derivatives. The company specializes in the development and production of complex chemistry-based products for the global pharmaceutical and generic drug industries. Its core portfolio includes APIs across diverse therapeutic areas such as oncology, cardiovascular, and anti-diabetics. Additionally, the company is a major producer of xanthines, including caffeine and theophylline. Aarti Pharmalabs offers comprehensive Contract Development and Manufacturing Organization (CDMO) services, leveraging its integrated research and development capabilities and large-scale manufacturing facilities. The organization maintains high regulatory standards, ensuring compliance with international quality benchmarks to serve a global clientele.

Recent filings

Filing Released Lang Actions
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 95% confidence The document is a notification to stock exchanges about an upcoming Earnings Conference Call scheduled to discuss the company's Q3/9M-FY24 financial results. It includes details such as date, time, dial-in numbers, and management participants. The document does not contain actual financial results or detailed financial statements but is an announcement of the call event. Therefore, it is not an Earnings Release (ER) itself, nor a full Interim/Quarterly Report (IR). It fits the category of a Call Transcript (CT) only if it contained the transcript, but here it is just an invitation. Hence, the best classification is Regulatory Filings (RNS) as a general regulatory announcement about the earnings call schedule, since it does not fit other categories and is a formal compliance notification under SEBI regulations.
2024-02-01 English
Board Meeting — AARTI PHARMALABS LIMITED has informed the Exchange about Board Meeting to be held on 07-Feb-2024 to consider and approve the Quarterly Audited Financial results of the Company for the…
Regulatory Filings
2024-01-30 English
Board Meeting — Financial Results/Dividend/Other business matters
Regulatory Filings Classification · 95% confidence The document is a formal letter addressed to stock exchanges notifying them of an upcoming Board Meeting scheduled for February 7, 2024. The letter references Regulation 29 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which pertains to disclosure of events or information by listed entities. The letter states that the Board will consider and approve the audited financial results for the quarter and nine months ended December 31, 2023, and also consider declaring an interim dividend. However, the document itself does not contain any financial results or detailed report; it is merely an intimation or announcement of the Board Meeting where such matters will be discussed and decided. The document length is short (1520 characters), and it serves as a notification rather than a report or detailed filing. Therefore, according to the rules, this is a Regulatory Filing (RNS) as it is a general regulatory announcement and does not fit into other specific categories like Interim Report or Earnings Release. It is not a report publication announcement because it does not mention the report being published or attached, only the meeting to consider the report.
2024-01-30 English
Certificate under SEBI (Depositories and Participants) Regulations, 2018
Regulatory Filings Classification · 95% confidence The document is a certificate issued under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018, confirming the dematerialisation of securities for the quarter ended December 31, 2023. It is addressed to stock exchanges and compliance departments, and it confirms procedural compliance related to securities dematerialisation and listing. The document is a regulatory compliance certificate rather than a financial report, earnings release, or management discussion. It does not contain financial statements or detailed financial data. It is also not an announcement of a report publication but a compliance certificate. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory compliance documents that do not fit other specific categories.
2024-01-08 English
ESOP/ESOS/ESPS
Capital/Financing Update Classification · 95% confidence The document is an official communication addressed to stock exchanges (BSE and NSE) regarding the grant of stock options under the company's Performance Stock Option Plan 2023. It references compliance with SEBI regulations and details the number of options granted, vesting period, exercise price, and other terms. This is a disclosure about a capital-related event, specifically the grant of stock options to employees, which affects the company's capital structure. It is not a financial report, earnings release, or management discussion. The document is an update on a capital/financing activity, consistent with the Capital/Financing Update (CAP) category.
2024-01-04 English
Trading Window
Regulatory Filings Classification · 95% confidence The document is a short notice addressed to stock exchanges regarding the closure of the trading window due to insider trading regulations around the announcement of quarterly financial results. It does not contain any financial data, report content, or detailed analysis. It is an announcement related to compliance and trading restrictions, not a financial report or earnings release. The document length is only 1165 characters, indicating it is a brief regulatory announcement. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for such compliance notices and miscellaneous regulatory announcements.
2023-12-28 English

Browse filings by year

4 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.